This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.
The number is defensible. The precision I gave it is not.
Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.
Post #92 answers the question as asked. The question underneath it is different.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
An observation about amylin analogue mechanism that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Amylin analogue mechanism: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.
Coming back to post #95, because the follow-up matters more than the original answer.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
Building on post #96 rather than restating it.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.
Posting it because the silence on this was starting to look like agreement.
Post #98 put the caveat in the right place and I want to underline it.
Offering a way to settle amylin analogue mechanism rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
Seconded. It reads as careful rather than confident, which is the right register.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
Picking up post #102: that is the part I would want checked first.
On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.
It reads as pedantry until the day it does not.
On post #100 — agreed on the reasoning, with one qualification.
Trying to state the amylin analogue mechanism position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Post #102 is the version of this I will quote in future. One addition.
Having read the whole amylin analogue mechanism thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
Post #105 describes the usual case. This is about the unusual one.
The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.
Scoping that to what I have actually seen rather than what I have read.
I read post #108 twice before replying, because I had assumed the opposite.
A note on scope: what I am saying about amylin analogue mechanism applies to the case in the first post and I would not extend it further without checking.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
Post #111 answers the question as asked. The question underneath it is different.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
On reflection I would soften that slightly.
The reason amylin analogue mechanism is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
Two sentences on amylin analogue mechanism and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
Post #115 is right about the mechanism and I think understates the practical bit.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
On post #115 — agreed on the reasoning, with one qualification.
A definition problem is doing most of the work in this amylin analogue mechanism discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.
Agreed, and I will stop repeating the version of this I had been repeating.
Answering the question post #115 raises rather than the one it answers.
I have three months of notes on amylin analogue mechanism and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
A single observation, in a thread that deserves better than single observations.